Hints and tips:
...Valuation dictates downgrade to Underperform: Over the last 3 years DiaSorin has traded at an average c.32% PE premium to select global diagnostic peers, reaching a peak c.60% premium and 37x 2021E PE in...
...The P/E troughed first in the GFC, then P and finally, much later, E (Figure 2). Earnings estimates do not turn until c.10 weeks after the trough in the market....
...The shares trade on a FY20E EV/EBIT of 11.3x (falling to 9.1x) and a P/E of 9.0x (falling to 5.7x)....
...With both the S&P 500 and STOXX 600 hovering near all-time highs, it is easy to think that investors are disregarding the economic impact of the Coronavirus outbreak....
...ratio of 1.0x and a DAX Shiller P/E of 12x....
...Roche has focused on two markets — oncology and diagnostics — and dominates both....
...C....
International Edition